Chongqing Precision Biotech Co., Ltd
Clinical trials sponsored by Chongqing Precision Biotech Co., Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New injection shows promise for tough lymphoma in early trial Results expected Dec 2026 (estimated)
- Engineered immune cells take aim at a shared marker in two blood cancers Results expected Jun 2027 (estimated)
-
Engineered immune cells take aim at Hard-to-Treat leukemias
Cure CompletedThis trial is testing a new type of immune cell therapy called CD123 CAR-NK cells in people with relapsed or refractory acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN). The cells are designed to find and attack cancer cells that carry a protei…
Phase 1/2 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Cure
Last updated Aug 07, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control CompletedThis trial investigates a type of immunotherapy called CAR-T cells that are designed to recognize and attack cancer cells carrying a protein called CEA. The study includes adults with advanced gastric, colon, rectal, esophageal, or pancreatic cancer who have not responded to at l…
Phase 1/2 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control CompletedThis early-stage trial tests a new type of cell therapy called CEA-targeted CAR-T for people with advanced colorectal, esophageal, stomach, or pancreatic cancers that have stopped responding to standard treatments. The therapy involves taking a patient's own immune cells, enginee…
Phase 1 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC